Kilambi News
Tuesday, November 17, 2026

FDA approves Imfinzi with Padcev for bladder cancer

Life Sciences Sunday, November 15, 2026 - Updated Nov 15, 2026 07:06

The FDA approved AstraZeneca Imfinzi with Astellas Padcev on November 13 for cisplatin ineligible muscle invasive bladder cancer, on VOLGA data cutting the risk of death by 42 percent.

Why it matters: Patients who cannot take cisplatin now have a second perioperative Padcev regimen, and AstraZeneca gains a third bladder approval for Imfinzi since 2025.

Data as of FDA approval notice and AstraZeneca release, both November 13, 2026, read in full. VOLGA results from a prespecified interim analysis with data cutoff March 2, 2026.

The Food and Drug Administration approved durvalumab, sold as Imfinzi by AstraZeneca, in combination with enfortumab vedotin-ejfv, sold as Padcev by Astellas, on November 13. The regimen is approved as neoadjuvant treatment before surgery, followed by single agent durvalumab as adjuvant treatment after radical cystectomy, for adults with muscle invasive bladder cancer who are ineligible for cisplatin based chemotherapy or have refused it.

The decision rests on VOLGA, a randomised open label Phase 3 trial that enrolled 695 patients who were candidates for bladder removal. Patients received three cycles of durvalumab with enfortumab vedotin before surgery, surgery alone, or an additional investigational combination. Median event free survival was not reached in the combination arm, against 12.1 months with surgery alone, a hazard ratio of 0.51. Overall survival also favoured the combination, with a hazard ratio of 0.58, which corresponds to the 42 percent reduction in the risk of death reported by AstraZeneca. The full results were presented at the ESMO Congress in 2026 and published in The New England Journal of Medicine.

The approved dosing gives durvalumab 1,500 mg every three weeks with enfortumab vedotin 1.25 mg per kilogram on days 1 and 8 for three cycles before surgery, then durvalumab every four weeks for up to nine cycles after surgery. Padcev is therefore used only before surgery in this regimen, unlike the competing Keytruda and Padcev regimen. The FDA lists the common adverse reactions, including rash, raised liver enzymes, peripheral neuropathy and fatigue, and durvalumab carries warnings for immune mediated adverse reactions. Independent coverage of the trial put grade 3 or higher adverse events at 71.1 percent on the regimen, a safety cost that sits alongside the survival gain.

The review ran under Project Orbis with regulators in Australia, Brazil, Canada, Israel, Singapore and the United Kingdom, and the FDA acted six weeks ahead of its goal date under priority review. AstraZeneca says applications based on VOLGA are under review in the European Union, Japan and other countries. For AstraZeneca, this is a third Imfinzi bladder milestone in two years, after the NIAGARA approval with chemotherapy in March 2025 and the POTOMAC approval in non muscle invasive disease in May 2026.

Sources

  1. FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer - US Food and Drug Administration - 2026-11-13
  2. Perioperative IMFINZI (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer - AstraZeneca - 2026-11-13